Genmab — Januar 2017
-
Mayflower - jeg det er forkert at sige at Janssen / Genmab ejer Darzalex 50/50
-
Det vi ved er at Genmab har tildelt Jansen en eksklusiv licens globalt til at udvikle og kommercialisere Daratumumab/CD38. Der er ikke nogen af os der er i stand til at dykke ned i det kontraktmæssige og afgrænsningen. Genmab ejer både patent og Daratumumab men har udlicensieret det.
-
Flot omsætning i dag også. Vi har lige passeret 500.000.000.

-
100.000 stk om dagen frem til recepttal vil være fint.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind